The report assesses the risks of PMMA, especially in association with the already controlled substance PMA (para-methoxyamphetamine). PMMA, is an amphetamine-like substance very close to PMA, and is almost exclusively sold in tablet form in combination with the latter and consumed as ‘ecstasy’. It has been associated, in combination with PMA, with three deaths in the EU. PMMA is devoid of any therapeutic value.

Further to the conclusions of the EMCDDA risk assessment, on 28 February 2002, the Council of the European Union adopted a unanimous decision defining the new synthetic drug PMMA (para-methoxymethylamphetamine) as a substance to be placed under control measures and criminal penalties in the EU Member States

Table of contents
• Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs
• Council decision
• Europol-EMCDDA progress report on PMMA and PMA
• Review of the pharmacotoxicological data on PMMA
• Sociological and criminological evidence on the risks of PMMA
• Public health risks of PMMA: epidemiological evidence